Physician profile
Daniel R Mesko
NPI 1164788378
$98,655.68
in general payments reported to CMS, 2019-2025
30 companies · $20K in 2025
The $20K reported for 2025 was more than what 82% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,359 · 2020: $605 · 2021: $11K · 2022: $12K · 2023: $17K · 2024: $34K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Food and Beverage: $4,628 · Travel and Lodging: $3,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,426.11 |
| Food and Beverage | $4,627.65 |
| Travel and Lodging | $3,666.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $75,836.79 | 2019-2025 | Mako, Triathlon, Trident |
| Depuy Synthes Products, INC. | $12,765.17 | 2021-2024 | Velys |
| Encore Medical, LP | $1,897.40 | 2021-2023 | Djo Surgical |
| Depuy Synthes Sales INC. | $1,803.97 | 2019-2023 | Reclaim, Monovisc, Orthovisc |
| Djo, LLC | $1,644.86 | 2021-2022 | |
| Omnilife Science, INC | $1,128.77 | 2021-2022 | |
| Smith+Nephew, INC. | $1,124.77 | 2019-2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Healicoil, Firstpass |
| Abbott Laboratories | $343.84 | 2022 | |
| Orthofix Medical, INC. | $343.42 | 2019-2025 | Physio-Stim, Cervical-Stim |
| Curonix LLC | $232.24 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Solventum Corporation | $226.16 | 2024-2025 | V.A.C. Veraflo, Prevena, V.A.C.Ulta |
| Vericel Corporation | $187.04 | 2021-2025 | Maci |
| Zimmer Biomet Holdings, INC. | $182.96 | 2022-2024 | Tapestry, Persona |
| Abbvie INC. | $147.31 | 2022-2023 | |
| Heron Therapeutics, INC. | $136.84 | 2022-2023 | Aponvie |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onkos Surgical, INC. | $116.52 | 2025 | Eleos Limb Salvage System |
| Next Science LLC | $104.69 | 2024 | Blastx, Surgx, Xperience |
| Medical Device Business Services, INC. | $84.00 | 2019 | |
| Boston Scientific Corporation | $62.86 | 2025 | General - Pain Management |
| Davol INC. | $53.23 | 2024 | Arista Ah Flexitip |
| Integra Lifesciences Corporation | $51.40 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Arthrosurface Incorporated | $44.11 | 2020 | |
| Pfizer INC. | $34.08 | 2022-2024 | |
| Dynasplint Systems INC. | $21.82 | 2019 | |
| Radius Health, INC. | $20.26 | 2024 | Tymlos |
| Ferring Pharmaceuticals INC. | $13.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.09 | 2023 | |
| Convatec INC. | $12.35 | 2019 | |
| Medtronic USA, INC. | $11.19 | 2019 | |
| Amgen INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mesko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.